Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines

View ORCID ProfileSeth Toback, Eva Galiza, Catherine Cosgrove, James Galloway, Anna L. Goodman, Pauline A. Swift, Sankarasubramanian Rajaram, Alison Graves-Jones, Jonathan Edelman, Fiona Burns, Angela M. Minassian, Iksung Cho, Lakshmi Kumar, Joyce S. Plested, E. Joy Rivers, Andreana Robertson, Filip Dubovsky, Greg Glenn, View ORCID ProfilePaul T. Heath on behalf of the 2019nCoV-302 Study Group
doi: https://doi.org/10.1101/2021.06.09.21258556
Seth Toback
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seth Toback
Eva Galiza
2Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Cosgrove
2Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Galloway
3Centre for Rheumatic Disease, King’s College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna L. Goodman
4Department of Infectious Diseases, Guy’s and St Thomas’ NHS Foundation Trust, and MRC Clinical Trials Unit at University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pauline A. Swift
5Department of Nephrology, Epsom and St. Helier University Hospitals NHS Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sankarasubramanian Rajaram
6Seqirus UK Limited, Maidenhead, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alison Graves-Jones
7Seqirus Australia Pty. Ltd., Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Edelman
8Seqirus USA Inc., Summit, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Burns
9Institute for Global Health, University College London, and Royal Free London NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela M. Minassian
10Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, and Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iksung Cho
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lakshmi Kumar
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce S. Plested
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Joy Rivers
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreana Robertson
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Dubovsky
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Greg Glenn
1Novavax, Inc., Gaithersburg, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pheath@sgul.ac.uk
Paul T. Heath
2Vaccine Institute, St. George’s, University of London and St. Georges University Hospitals NHS Foundation Trust, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul T. Heath
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background The safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines has not yet been reported.

Methods A sub-study on influenza vaccine co-administration was conducted as part of the phase 3 randomized trial of the safety and efficacy of NVX-CoV2373. The first ∼400 participants meeting main study entry criteria and with no contraindications to influenza vaccination were invited to join the sub-study. After randomization in a 1:1 ratio to receive NVX-CoV2373 (n=217) or placebo (n=214), sub-study participants received an age-appropriate, licensed, open-label influenza vaccine with dose 1 of NVX-CoV2373. Reactogenicity was evaluated via electronic diary for 7 days post-vaccination in addition to monitoring for unsolicited adverse events (AEs), medically-attended AEs (MAAEs), and serious AEs (SAEs). Influenza haemagglutination inhibition and SARS-CoV-2 anti-spike IgG assays were performed. Vaccine efficacy against PCR-confirmed, symptomatic COVID-19 was assessed. Comparisons were made between sub-study and main study participants.

Findings Sub-study participants were younger, more racially diverse, and had fewer comorbid conditions than main study participants. Reactogenicity events more common in the co-administration group included tenderness (70.1% vs 57.6%) or pain (39.7% vs 29.3%) at injection site, fatigue (27.7% vs 19.4%), and muscle pain (28.3% vs 21.4%). Rates of unsolicited AEs, MAAEs, and SAEs were low and balanced between the two groups. Co-administration resulted in no change to influenza vaccine immune response, while a reduction in antibody responses to the NVX-CoV2373 vaccine was noted. Vaccine efficacy in the sub-study was 87.5% (95% CI: -0.2, 98.4) while efficacy in the main study was 89.8% (95% CI: 79.7, 95.5).

Interpretation This is the first study to demonstrate the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with seasonal influenza vaccines. The results suggest concomitant vaccination may be a viable immunisation strategy.

Funding This study was funded by Novavax, Inc.

Evidence before this study We searched PubMed for research articles published from December 2019 until 1 April 2021 with no language restrictions for the terms “SARS-CoV-2”, “COVID-19”, “vaccine”, “co-administration”, and “immunogenicity”. There were no peer-reviewed publications describing the simultaneous use of any SARS-CoV-2 vaccine and another vaccine. Several vaccine manufacturers had recent publications on phase 3 trials results (Pfizer/BioNTech, Moderna, AstraZeneca, Janssen, and the Gamaleya Research Institute of Epidemiology and Microbiology). Neither these publications nor their clinical trials’ protocols (when publicly available) described co-administration and they often had trial criteria specifically excluding those with recent or planned vaccination with any licenced vaccine near or at the time of any study injection.

Added value of this study Immune interference and safety are always a concern when two vaccines are administered at the same time. This is the first study to demonstrate the safety and immunogenicity profile and clinical vaccine efficacy of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine.

Implications of all the available evidence This study provides much needed information to help guide national immunisation policy decision making on the critical issue of concomitant use of COVID-19 vaccines with influenza vaccines.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04583995; https://clinicaltrials.gov/ct2/show/NCT04583995

Clinical Protocols

https://www.medrxiv.org/content/10.1101/2021.05.13.21256639v1.supplementary-material

https://www.novavax.com/sites/default/files/2021-04/2019nCoV_302_Phase3UK%20_Version4_Redacted.pdf

https://clinicaltrials.gov/ct2/show/NCT04583995

Funding Statement

This study was funded by Novavax, Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial protocol was approved by the North West Greater Manchester Central Research Ethics Committee (Ref 20/NW/03/99) and was performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines. Safety oversight was performed by an independent safety monitoring committee.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Listed in the Supplemental Material.

Data Availability

The protocol for this phase 3 study is publicly available from Novavax.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
Seth Toback, Eva Galiza, Catherine Cosgrove, James Galloway, Anna L. Goodman, Pauline A. Swift, Sankarasubramanian Rajaram, Alison Graves-Jones, Jonathan Edelman, Fiona Burns, Angela M. Minassian, Iksung Cho, Lakshmi Kumar, Joyce S. Plested, E. Joy Rivers, Andreana Robertson, Filip Dubovsky, Greg Glenn, Paul T. Heath
medRxiv 2021.06.09.21258556; doi: https://doi.org/10.1101/2021.06.09.21258556
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
Seth Toback, Eva Galiza, Catherine Cosgrove, James Galloway, Anna L. Goodman, Pauline A. Swift, Sankarasubramanian Rajaram, Alison Graves-Jones, Jonathan Edelman, Fiona Burns, Angela M. Minassian, Iksung Cho, Lakshmi Kumar, Joyce S. Plested, E. Joy Rivers, Andreana Robertson, Filip Dubovsky, Greg Glenn, Paul T. Heath
medRxiv 2021.06.09.21258556; doi: https://doi.org/10.1101/2021.06.09.21258556

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8983)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1953)
  • Geriatric Medicine (190)
  • Health Economics (401)
  • Health Informatics (1328)
  • Health Policy (659)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10801)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1827)
  • Nursing (110)
  • Nutrition (272)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (997)
  • Ophthalmology (297)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (579)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1898)
  • Public and Global Health (4122)
  • Radiology and Imaging (675)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (80)